Description of the role of Intracrinology for the physiological treatment of vulvovaginal atrophy (VVA)
Endoceutics

Saturday, November 24, 2018                                                                                                                                                     ST. JAMES 
12:10 – 13:40 SESSION 3
Description of the role of Intracrinology for the physiological treatment of vulvovaginal atrophy (VVA)

Supported by Endoceutics
Capsule After menopause, dehydroepiandrosterone (DHEA) becomes the exclusive source of both estrogens and androgens. The decrease in serum DHEA causes a deprivation of intracellular sex steroids which is the main cause of the symptoms of menopause, including VVA. The intravaginal administration of DHEA, by a strictly local action, corrects the symptoms and signs of VVA while all serum steroids remain within normal values, thus avoiding abnormal systemic exposure.
Chairpersons Fernand Labrie, Canada
Santiago Palacios, Spain
Intracrinology – The lack of DHEA, the exclusive source of sex steroids, becomes the main cause of menopausal symptoms, including VVA, in postmenopausal women
Fernand Labrie, Canada
Healthy and sex steroid-deprived vagina – From preclinical to clinical characteristics
Céline Bouchard, Canada
Intravaginal prasterone, novel and non-estrogen efficacious therapy for vulvovaginal atrophy
Santiago Palacios, Spain